INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Ventyx Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On December 2, 2025, Ventyx announced a revision of its guidance for the topline data release from the interim analysis of its Phase 2 study of VTX2735, now expected in Q1 2026 [3] - The CEO indicated that this shift allows for the introduction of dose-ranging studies with a new once-daily formulation and expansion into Canada, the EU, and the UK, which is believed to accelerate Phase 3 timelines [3] - Following this announcement, Ventyx's stock price decreased by $1.44 per share, or 15.35%, closing at $7.94 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Ventyx regarding potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]